Inhibiting crucial factors in the m6A pathway, like METTL3 and HIF-1α, can offer novel treatment strategies for NSCLC, particularly for smoking-related patients (191).Research also indicates that METTL3 regulates the expression of resistance-related genes via m6A modification, such as enhancing SOX2 stability to promote cisplatin resistance. This evidence concerns the gene METTL3 and non-small cell lung carcinoma.